Nurix Therapeutics suffered its worst one-day loss as a public company Wednesday, nosediving 38% after Sanofi terminated ...

Novartis has confirmed nine instances—seven of them newly disclosed—in which tumors have developed in children treated with its marketed spinal muscular atrophy gene therapy Zolgensma® (onasemnogene ...

Its first program is an investigational therapy program for ornithine transcarbamylase deficiency, a rare, X-linked metabolic disorder.

Researchers say to their knowledge the study represents the largest study to date of PFAS exposure and breast cancer incidence, particularly for ER-tumors.

Personalized grafts, bioinks, and off-the-shelf tissues are advancing regenerative medicine toward broader clinical use.

Researchers say findings establish HOX genes as potential therapeutic targets for enhancing bone regeneration.

Process analytical technology (PAT) bioprocess monitoring instruments generally are designed for large-scale processes, which ...

Principal Scientist, USP While payload design will remain a primary focus, the next era of innovation in CGT may ultimately ...

Lonza plans to more than double its U.S. footprint of CDMO sites by agreeing to acquire five such sites in the U.S. from Merck KGaA, Darmstadt, Germany, in a deal the companies would only say was ...

Differing apheresis practices at collection sites have a significant impact on samples and, therefore, the quality of cell ...

Despite this advance, conventional CRISPR-Cas9 systems may introduce potentially harmful DNA breaks and cannot easily be ...

Recursion said it expects to launch its first registrational trial in the second half of this year for its lead candidate REC-4881 based on talks with the FDA, after the oral familial adenomatous ...